Overview

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Status:
Active, not recruiting
Trial end date:
2038-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. In addition, information on disease status and quality of life will be collected.
Details
Lead Sponsor:
Janssen Biotech, Inc.
Treatments:
Infliximab